Report Overview
Clinical Oncology Next Generation Sequencing (NGS) refers to advanced genetic sequencing technologies used to analyze various types of genetic mutations, including single-nucleotide variations, insertions, deletions, exon duplications, gene copy number changes, and translocations.
These technologies play a crucial role in precision medicine, allowing for targeted cancer therapies and personalized treatment approaches.
Market Analysis
The global Clinical Oncology Next Generation Sequencing (NGS) Market was valued at approximately USD 704.70 million in 2023 and is projected to reach USD 1745.02 million by 2032, growing at a CAGR of 10.60%.
North America remains a dominant player, with an estimated market size of USD 218.51 million in 2023, growing at a CAGR of 9.09% from 2025 through 2032.
Regional Analysis
North America
Europe
Asia-Pacific
South America
Middle East & Africa
Analysis
Bioscience
